Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-Current Assets (2019 - 2025)

Eton Pharmaceuticals' Non-Current Assets history spans 7 years, with the latest figure at $32.5 million for Q3 2025.

  • For Q3 2025, Non-Current Assets rose 433.65% year-over-year to $32.5 million; the TTM value through Sep 2025 reached $134.9 million, up 464.2%, while the annual FY2024 figure was $35.1 million, 616.22% up from the prior year.
  • Non-Current Assets for Q3 2025 was $32.5 million at Eton Pharmaceuticals, down from $33.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $35.1 million in Q4 2024 and bottomed at $743000.0 in Q3 2021.
  • The 5-year median for Non-Current Assets is $4.9 million (2023), against an average of $10.4 million.
  • The largest annual shift saw Non-Current Assets crashed 53.85% in 2021 before it surged 616.22% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $3.9 million in 2021, then surged by 30.17% to $5.0 million in 2022, then dropped by 2.49% to $4.9 million in 2023, then soared by 616.22% to $35.1 million in 2024, then decreased by 7.38% to $32.5 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Non-Current Assets are $32.5 million (Q3 2025), $33.2 million (Q2 2025), and $34.1 million (Q1 2025).